Alex Manick is an Associate Principal focused on venture and growth stage investments. She currently serves as a Director at Remedy Plan Therapeutics. Prior to Schooner, she worked as a process engineer for MIT spin-out start-up, 1366 Technologies, analyzed automobile manufacturing practices for the CTO at Tesla Motors, and consulted for various early stage tech companies. Alex holds a BS in Materials Science & Engineering from MIT and an MBA from Stanford University.